Results of the Phase II GAGE Trial in CLL

June 11, 2014
Joseph M. Flynn, DO, MPH

Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).

Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).

Clinical Pearls:

  • Obinutuzumab is a type II, anti-CD20 monoclonal antibody.
  • Earlier trials examining obinutuzumab in CLL demonstrated single-agent activity with suggestion of a dose response.​
  • In this phase II multicenter study, 80 patients were randomized to receive either 1000 mg or 2000 mg of obinutuzumab.
  • Results showed the overall response rate (ORR) was 67% in the 2000mg arm vs 49% in the 1000 mg arm. However, this data was not statistically significant.
  • The safety profile was consistent with other monoclonal antibodies.